Torrent Pharmaceuticals Ltd Q4 FY26 Earnings Analysis

- India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. (Page 4) - Brazil branded generics market grew 10% YoY; Torrent grew 13% with healthy volume growth and mid-single digit pricing increase; expects 5-6 new product launches in Brazil. (Pages 3, 14) - U.S. business saw 12% growth in constant currency; targeting a directional increase in sales with at least 5-7 launches per year and aims to cross $200 million annual sales by FY27. (Pages 3, 9) - Germany facing supply disruptions, growth affected; alternative supplier efforts ongoing but will take 3-4 quarters. (Page 4) - JB Pharma acquisition synergy target INR 400-450 crores over 2-3 years, largely cost synergies initially; revenue synergies expected after integration. (Pages 6, 14) - Medium-term focus on growth in emerging markets like Russia, Mexico, Philippines toward $50 million markets over 3-4 years. (Page 12)

- Torrent Pharma expects continued healthy double-digit growth in India and Brazil businesses. - India business grew 14% in Q3 FY26 and aims to sustain above-market volume growth supported by new products and price increases. - In Brazil, a 10% constant currency revenue growth was reported with an outlook of 10-15% growth driven by new launches and volume; market growth is 6-7%. - U.S. business (~$36 million revenue) aims to surpass $200 million sales by FY27, driven by 5-7 launches per year. - Cost synergies from JB acquisition targeted at INR 400-450 crores over 2-3 years, with up to 20% realized in year one and scaling thereafter. - JB’s EBITDA margin expected to improve from ~28-29% closer to Torrent’s 32-33% over time post-merger. - Net debt expected to reduce, with net debt to EBITDA ratio reducing to ~0.6 by FY29. - Overall operating EBITDA margin stable around 32.9%, with margin upside from synergies post-JB integration.

- There is no explicit mention of current or future capex/capital investment or strategic investment in the provided pages (up to page 15). - However, there is mention of ongoing work to address supply disruptions in Germany by moving some products to Torrent's own facilities, which implies some capital investment in manufacturing (Page 4). - For GLP-1 injectable products, Torrent does not have fill and finish capacity and will partner for manufacturing and launch, indicating a strategic partnership approach rather than immediate capex (Page 4). - The company is preparing future large markets like Russia, Mexico, and the Philippines for growth, which may involve strategic investments but no direct capex details are provided (Page 12). - Overall, the focus appears to be on integration with the JB acquisition, operational synergies, and expanding market presence rather than large announced capex at this stage.

- No explicit mention of any current or planned new fundraising through equity or debt in the call. - Net debt as of December is roughly INR 880 crores. - Post-acquisition, net EBITDA to net debt ratio is expected to improve with net debt to EBITDA around 1-1.1x in FY '28 and approximately 0.6x by FY '29. - Average cost of interest is about 7.6%. - The company is targeting to repay debt and get back to a net cash position possibly by FY '29, indicating no immediate new debt raising plans. - Focus appears on cost synergies and margin improvement rather than raising new funds.

The transcript in the provided pages does not explicitly mention specific details about the current or expected order book or pending orders for Torrent Pharmaceuticals Limited. However, related insights include: - The company has a robust pipeline, for example, 60 molecules awaiting approval at ANVISA (Brazil). - Ongoing active launch plans, including for products like Semaglutide, though some launches may be delayed to the next financial year. - The acquired JB Pharmaceuticals business is being integrated, with expected synergies and growth resuming post-Q4. - Continuous focus on expanding footprint in key markets (India, Brazil, US, Germany) and building future markets like Russia, Mexico, and the Philippines. - The business maintains a healthy demand generation (e.g., OTC Curatio business growing 27%) and volume growth above market in India. Specific numeric order book or pending order figures are not disclosed in the call transcript.